Just In
Priya Nair to succeed Rohit Jawa as the MD and CEO of HUL, effective 1st August.
TCS records a Total Contract Value (TCV) of $9.4 billion in Q1 FY26.
“We saw robust deal closures during this quarter. We remain closely connected to our customers to help them navigate the challenges impacting their business through, among others, AI-led transformation,” K Krithivasan, CEO and MD, TCS.
“The continued global macroeconomic and geopolitical uncertainties caused a demand contraction (in the quarter),” K Krithivasan, CEO and MD, TCS.
Priya Nair to succeed Rohit Jawa as the MD and CEO of HUL, effective 1st August.
TCS records a Total Contract Value (TCV) of $9.4 billion in Q1 FY26.
“We saw robust deal closures during this quarter. We remain closely connected to our customers to help them navigate the challenges impacting their business through, among others, AI-led transformation,” K Krithivasan, CEO and MD, TCS.
“The continued global macroeconomic and geopolitical uncertainties caused a demand contraction (in the quarter),” K Krithivasan, CEO and MD, TCS.

Biocon

(27 search results)

Biocon shares drop 6% after USFDA inspection of Malaysian unit
Biocon shares down 5% on 30% dip in Q1 profit
Why Cancer Is The New Cardiology For Hospital Chains
Biocon shares jump 7% on strong Q4, dividend declaration
Serum Institute to double its investment in Biocon subsidiary to $300 mn
Biocon says 'all product approvals are legitimate' in bribery case for insulin approval
Covid-19 put spotlight on vaccines, diagnostics: Mazumdar-Shaw
Biocon developing 20 biosimilar products for global markets
Biocon wins US patent battle against Sanofi on insulin biosimilar
Nykaa’s Falguni now richer than Havells, Marico, Eicher and Biocon owners